← Back to Search

Anti-metabolite

NaliCap for Pancreatic Cancer (NaliCap Trial)

Phase 2
Recruiting
Research Sponsored by Seoul National University Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Summary

This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free survival
Secondary study objectives
Adverse events
Objective response rate
Overall survival
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NaliCapExperimental Treatment2 Interventions
nal-IRI/Capecitabine
Group II: NAPOLIActive Control3 Interventions
nal-IRI/5-FU/LV
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
FDA approved

Find a Location

Who is running the clinical trial?

Seoul National University HospitalLead Sponsor
1,886 Previous Clinical Trials
6,301,351 Total Patients Enrolled
Do-Youn Oh, M.D., PhD.Study DirectorSeoul National University Hospital
2 Previous Clinical Trials
120 Total Patients Enrolled
~11 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top